abstract |
The present invention provides (a) a physical interaction (binding) between MUC1 and a tumor progression factor (eg, β-catenin, c-Src, EGF-R, p120 ctn , or PKCδ ), and / or (b) It features a method of identifying compounds that inhibit phosphorylation by tumor progression factors (eg, c-Src, EGF-R, or PKCδ) with MUC1 kinase activity. The invention also includes a method of inhibiting the interaction between MUC1 and β-catenin and a method of inhibiting the expression of MUC1 or tumor progression factor in a cell. |